These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7590519)

  • 21. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
    Pearce RK; Smith LA; Jackson MJ; Banerji T; Scheel-Krüger J; Jenner P
    Mov Disord; 2002 Sep; 17(5):877-86. PubMed ID: 12360536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M; Stahl S; Jenner P; Marsden CD
    Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marmoset monkey models of Parkinson's disease: which model, when and why?
    Eslamboli A
    Brain Res Bull; 2005 Dec; 68(3):140-9. PubMed ID: 16325013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus).
    Uehara S; Uno Y; Inoue T; Murayama N; Shimizu M; Sasaki E; Yamazaki H
    Drug Metab Dispos; 2015 May; 43(5):735-42. PubMed ID: 25735838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Miwa T; Watanabe A; Mitsumoto Y; Furukawa M; Fukushima N; Moriizumi T
    Acta Otolaryngol Suppl; 2004 Aug; (553):80-4. PubMed ID: 15277042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.
    Nomoto M; Jenner P; Marsden CD
    Neurosci Lett; 1988 Nov; 93(2-3):275-80. PubMed ID: 2907373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
    Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1995 Feb; 117(3):287-97. PubMed ID: 7770604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1994 Oct; 264(2):117-23. PubMed ID: 7851473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
    Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
    Hille CJ; Fox SH; Maneuf YP; Crossman AR; Brotchie JM
    Exp Neurol; 2001 Nov; 172(1):189-98. PubMed ID: 11681851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recent progress in development of psychotropic drugs (3)--Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals].
    Nomoto M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Aug; 16(4):113-22. PubMed ID: 8905800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Central and peripheral catecholamine depletion by 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in rodents.
    Fuller RW; Steranka LR
    Life Sci; 1985 Jan; 36(3):243-7. PubMed ID: 3871244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease.
    Verhave PS; Vanwersch RA; van Helden HP; Smit AB; Philippens IH
    Behav Brain Res; 2009 Jun; 200(1):214-9. PubMed ID: 19378465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
    Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
    Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease.
    Fisher R; Lincoln L; Jackson MJ; Abbate V; Jenner P; Hider R; Lees A; Rose S
    Phytother Res; 2018 Apr; 32(4):678-687. PubMed ID: 29368409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
    Willis GL; Robertson AD
    Pharmacol Biochem Behav; 2005 Jan; 80(1):9-26. PubMed ID: 15652376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1993 Jul; 238(2-3):235-40. PubMed ID: 8104807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
    Nomoto M; Jenner P; Marsden CD
    Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment.
    Hurley MJ; Jolkkonen J; Stubbs CM; Jenner P; Marsden CD
    Brain Res; 1996 Feb; 709(2):259-64. PubMed ID: 8833762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.